Profile of ipilimumab and its role in the treatment of metastatic melanoma

被引：34
作者：
Patel, Sapna P. [1 ]
Woodman, Scott E. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol Dept, Houston, TX 77054 USA
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2011年 / 5卷
关键词：
ipilimumab; melanoma; T-cells; CTLA-4; T-LYMPHOCYTE ANTIGEN-4; PHASE-II; TUMOR-REGRESSION; IV MELANOMA; STAGE-III; CTLA-4; BLOCKADE; AUTOIMMUNITY; INTERLEUKIN-2; THERAPY;
D O I：
10.2147/DDDT.S10945
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Melanoma is an immunogenic cancer. However, the ability of the immune system to eradicate melanoma tumors is affected by intrinsic negative regulatory mechanisms. Multiple immune-modulatory therapies are currently being developed to optimize the immune response to melanoma tumors. Two recent Phase III studies using the monoclonal antibody ipilimumab, which targets the cytotoxic T-lymphocyte antigen (CTLA-4), a negative regulator of T-cell activation, have demonstrated improvement in overall survival of metastatic melanoma patients. This review highlights the clinical trial data that supports the efficacy of ipilimumab, the immune-related response criteria used to evaluate clinical response, and side-effect profile associated with ipilimumab treatment.
引用
收藏
页码：489 / 495
页数：7
相关论文
共 44 条
  • [1] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Adjei, Alex A.
    Cohen, Roger B.
    Franklin, Wilbur
    Morris, Clive
    Wilson, David
    Molina, Julian R.
    Hanson, Lorelei J.
    Gore, Lia
    Chow, Laura
    Leong, Stephen
    Maloney, Lara
    Gordon, Gilad
    Simmons, Heidi
    Marlow, Allison
    Litwiler, Kevin
    Brown, Suzy
    Poch, Gregory
    Kane, Katie
    Haney, Jerry
    Eckhardt, S. Gail
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2139 - 2146
  • [2] [Anonymous], 2007, ONE MONTH INTRAVENOU
  • [3] [Anonymous], IMMUNE MEDIATED ADVE
  • [4] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [5] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    Attia, P
    Phan, GQ
    Maker, AV
    Robinson, MR
    Quezado, MM
    Yang, JC
    Sherry, RM
    Topalian, SL
    Kammula, US
    Royal, RE
    Restifo, NP
    Haworth, LR
    Levy, C
    Mavroukakis, SA
    Nichol, G
    Yellin, MJ
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6043 - 6053
  • [6] Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
    Besser, Michal J.
    Shapira-Frommer, Ronnie
    Treves, Avraham J.
    Zippel, Dov
    Itzhaki, Orit
    Hershkovitz, Liat
    Levy, Daphna
    Kubi, Adva
    Hovav, Einat
    Chermoshniuk, Natalia
    Shalmon, Bruria
    Hardan, Izhar
    Catane, Raphael
    Markel, Gal
    Apter, Sara
    Ben-Nun, Alon
    Kuchuk, Iryna
    Shimoni, Avichai
    Nagler, Arnon
    Schachter, Jacob
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (09) : 2646 - 2655
  • [7] KIT as a Therapeutic Target in Metastatic Melanoma
    Carvajal, Richard D.
    Antonescu, Cristina R.
    Wolchok, Jedd D.
    Chapman, Paul B.
    Roman, Ruth-Ann
    Teitcher, Jerrold
    Panageas, Katherine S.
    Busam, Klaus J.
    Chmielowski, Bartosz
    Lutzky, Jose
    Pavlick, Anna C.
    Fusco, Anne
    Cane, Lauren
    Takebe, Naoko
    Vemula, Swapna
    Bouvier, Nancy
    Bastian, Boris C.
    Schwartz, Gary K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2327 - 2334
  • [8] Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells
    Chambers, CA
    Sullivan, TJ
    Allison, JP
    [J]. IMMUNITY, 1997, 7 (06) : 885 - 895
  • [9] PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    Curran, Michael A.
    Montalvo, Welby
    Yagita, Hideo
    Allison, James P.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) : 4275 - 4280
  • [10] Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
    Downey, Stephanie G.
    Klapper, Jacob A.
    Smith, Franz O.
    Yang, James C.
    Sherry, Richard M.
    Royal, Richard E.
    Kammula, Udai S.
    Hughes, Marybeth S.
    Allen, Tamika E.
    Levy, Catherine L.
    Yellin, Michael
    Nich, Geoffrey
    White, Donald E.
    Steinberg, Seth M.
    Rosenberg, Steven A.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (22) : 6681 - 6688
12345